Other News To Note

Ensemble Therapeutics Corp., of Cambridge, Mass., triggered a milestone payment from partner Bristol-Myers Squibb Co., of Princeton, N.J., by developing an Ensemblin-based therapeutic against one of the targets in their collaboration. Achievement of the milestone was based on specific criteria of the drug, including potency, selectivity and pharmacokinetics. That drug target program will now transition to BMS for development.